PopGenTech and Quintiles Partner to Apply Large-Scale Sequencing to Drug Development
May 17, 2011
PopGenTech and Quintiles Partner to Apply Large-Scale Sequencing to Drug Development
The companies' first project will be a renal cancer clinical trial for an undisclosed Quintiles client. The partners aim to identify genetic markers that are predictive of adverse events and efficacy.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sequencing Has Small but Growing Role in Clinical Trials and Drug Development
October 12, 2011 / Clinical Sequencing News - At Investor Confab, Illumina Details 'Enormous' DTC Demand as Market Shifts to Less Complex Chips
May 21, 2013 / BioArray News - ICCG, Awaiting Funding, Moves Ahead with Plans to Build Database of Genomic, Phenotypic Information
May 21, 2013 / BioArray News - Sequencing of Cell-Free DNA Holds Promise for Monitoring Cancer During Treatment, Study Suggests
March 20, 2013 / Clinical Sequencing News - Boreal Develops OnTarget System for Non-Invasive Cancer Mutation Monitoring
March 20, 2013 / Clinical Sequencing News